10-Q: AdaptHealth Q1 2026 Earnings: Revenue Up, Net Loss Widens

AdaptHealth Corp. reported a 5.4% increase in net revenue for Q1 2026, reaching $819.8 million, but experienced a wider net loss of $16.0 million compared to the prior year.

Summary

• AdaptHealth Corp. reported net revenue of $819.8 million for the first quarter ended March 31, 2026, an increase of 5.4% compared to $777.9 million in the same period last year.
• The company experienced a net loss attributable to AdaptHealth Corp. of $16.0 million for the quarter, a significant increase from the $7.2 million net loss reported in Q1 2025.
• Adjusted EBITDA decreased by 5.3% to $121.2 million from $127.9 million in the prior year period.
• The Sleep Health segment saw a 13.3% revenue increase, while Respiratory Health revenue grew by 7.6%. Diabetes Health revenue increased by 2.4%, and Wellness at Home revenue decreased by 10.3%.
• The company completed two acquisitions during the quarter for $84.7 million to support newly awarded at-risk capitated contracts.
• AdaptHealth refinanced its debt on April 10, 2026, entering into a new credit agreement with a maturity in April 2031.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the widening net loss, declining Adjusted EBITDA, and negative free cash flow, despite revenue growth.

Positives

• Net revenue increased by 5.4% to $819.8 million, driven by organic growth and acquisitions.
• The Sleep Health segment revenue grew by 13.3% to $358.5 million, supported by capitated contracts and increased sales of PAP resupply products.
• Respiratory Health segment revenue increased by 7.6% to $178.1 million, also benefiting from capitated arrangements and higher oxygen equipment demand.
• The company successfully refinanced its debt, securing a new credit facility with a longer maturity, providing financial flexibility.
• The company is cooperating with ongoing investigations and has reached an agreement in principle to settle a shareholder class action lawsuit, with a significant portion funded by insurance.

Negatives

• Net loss attributable to AdaptHealth Corp. widened to $16.0 million from $7.2 million in the prior year.
• Adjusted EBITDA decreased by 5.3% to $121.2 million.
• The Wellness at Home segment experienced a 10.3% decrease in net revenue, largely due to the disposition of certain businesses.
• Free cash flow was negative $27.5 million, a significant decrease from negative $0.1 million in the prior year, primarily due to increased capital expenditures for patient equipment.
• The company faces ongoing legal proceedings, including shareholder derivative complaints and a civil investigative demand from the U.S. Attorney's Office related to billing practices.

Risks

• Potential for increased compliance costs and administrative burden due to CMS actions like temporary enrollment moratoria and heightened screening for DMEPOS supplier types.
• The company's ability to expand, pursue acquisitions, or maintain operational flexibility could be impacted by CMS enrollment moratoria.
• Inflationary pressures on materials, labor, shipping, and transportation could adversely impact costs and margins, with uncertainty regarding the ability to pass these costs to customers.
• The company is subject to ongoing legal proceedings, including shareholder class actions and derivative suits, which could result in material adverse outcomes.
• The company is cooperating with civil investigative demands from the U.S. Attorney's Office concerning billing practices for humidifiers and respiratory devices, with an uncertain impact on the company.
• The company's financial condition and results of operations could be materially adversely affected if additional financing is unavailable on acceptable terms.

Future Outlook

The company expects its operating cash flows, along with existing cash and available credit, to be sufficient for operations and growth strategies for at least the next twelve months. AdaptHealth may seek additional equity or debt financing for business growth, particularly for acquisitions.

Management Comments

• Management believes that organic revenue provides visibility into how AdaptHealth changes organically, that is, within its existing operations using its own resources.
• Management believes Adjusted EBITDA and Adjusted EBITDA Margin are useful to investors in evaluating AdaptHealth's financial performance.
• Management believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate AdaptHealth's competitors and to measure the ability of companies to service their debt.
• Management believes that its expected operating cash flows, together with its existing cash and amounts available under its existing credit agreement, will continue to be sufficient to fund its operations and growth strategies for at least the next twelve months.

Industry Context

StockSavvy.ai notes that AdaptHealth's performance in the healthcare-at-home sector reflects broader industry trends towards decentralized care and increased demand for home medical equipment and services, particularly in sleep and respiratory health. However, the company's results also highlight challenges such as rising costs and regulatory scrutiny common across the healthcare services industry.

Comparison to Industry Standards

• AdaptHealth's net revenue growth of 5.4% in Q1 2026 is moderate compared to some high-growth segments within the broader healthcare technology sector, but aligns with mature providers in the home medical equipment space.
• The decline in Adjusted EBITDA margin from 16.4% to 14.8% suggests potential margin pressure, which is a concern for many companies in the healthcare services industry facing increased operational costs and reimbursement challenges.
• The negative free cash flow of $27.5 million is a point of concern, as many investors look for positive free cash flow generation as a sign of financial health and ability to reinvest in the business or return capital to shareholders. This contrasts with companies that are able to consistently generate positive free cash flow.
• The company's significant investment in patient equipment ($121.2 million in Q1 2026) to support capitated arrangements is a strategic move that aligns with value-based care models, but requires careful management to ensure profitability compared to competitors focusing on fee-for-service models.

Legal Proceedings

• A consolidated class action complaint alleges violations of federal securities laws regarding billing practices and compliance programs, with an agreement in principle to settle for $35 million ($1 million paid by the company, $34 million by insurance).
• Shareholder derivative complaints allege breaches of fiduciary duties and violations of federal securities laws related to billing practices and compliance programs.
• A shareholder derivative complaint alleges breach of fiduciary duty, insider trading, and unjust enrichment.
• A class action lawsuit concerning North Carolina residents alleges violations of the Debt Collection Practices Act related to improper billing and late fees after equipment return, with an agreement to settle for $14.5 million.
• Civil investigative demands from the U.S. Attorney's Office in South Carolina and Pennsylvania are investigating potential violations of the False Claims Act related to billing for humidifiers and respiratory devices.

Related Party Transactions

• The company has an equity interest in a vendor providing automated order intake software, with expenses of $5.4 million in Q1 2026.
• A director serves on the board of a third-party payor that accounts for approximately 1.0% of consolidated net revenue.
• A director is an employee of a beneficial owner of more than 5% of the company's stock, which is also a minority shareholder of a vendor supplying medical equipment and supplies. Payments to this vendor were $23.6 million in Q1 2026.

Stakeholder Impact

• Shareholders: Negative impact due to widening net loss, declining Adjusted EBITDA, and negative free cash flow, despite revenue growth. Legal settlements and ongoing investigations also pose risks.
• Employees: Potential impact from increased operational costs and any restructuring related to segment performance or acquisitions. Equity-based compensation remains a significant expense.
• Customers (Patients): Continued provision of home medical equipment and supplies. Potential impact from regulatory changes affecting access to services.
• Suppliers: Continued business relationships, with potential for increased costs due to inflation impacting AdaptHealth's purchasing power.
• Creditors: Refinancing of debt provides a more stable capital structure, but covenants and leverage ratios remain important considerations.

Next Steps

• Continue to monitor the impact of CMS actions on enrollment and expansion.
• Manage inflationary pressures and operational costs to improve margins.
• Successfully integrate acquisitions and manage the transition of patients related to new capitated contracts.
• Continue cooperation with ongoing investigations and finalize the settlement of the shareholder class action lawsuit.
• Monitor the effectiveness and compliance with the new 2026 Credit Agreement.

Key Dates

Recommendation

While revenue growth is positive, the widening net loss, declining Adjusted EBITDA, and negative free cash flow are significant concerns. The company's debt refinancing provides some stability, but ongoing legal issues and regulatory risks warrant a cautious approach. A 'hold' recommendation reflects the mixed financial performance and the need for further operational improvements and resolution of legal matters before considering a more positive stance.

Keywords

AdaptHealth, 10-Q, Quarterly Report, Healthcare at Home, Home Medical Equipment, HME, Sleep Health, Respiratory Health, Diabetes Health, Wellness at Home, Net Revenue, Adjusted EBITDA, Net Loss, Financial Statements, SEC Filing